Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
The Medical Journal of Australia|September 12, 2022
Changes to design and analysis elements of research plans during randomised controlled trials in AustraliaXanthi Coskinas, R John Simes, Andrew J MartinContemporary Clinical Trials|August 28, 2021
Reacting to prognostic covariate imbalance in randomised controlled trialsXanthi Coskinas, I Manjula Schou, John Simes, et al.Trials|June 5, 2020
Changes to aspects of ongoing randomised controlled trials with fixed designsXanthi Coskinas, John Simes, Manjula Schou, et al.Breast Cancer Research and Treatment|October 18, 2008
Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial)Michaella J Smith, P Grantley Gill, Neil Wetzig, et al.Kidney Cancer (Clifton, Va.)|February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUPMartin R Stockler, Andrew J Martin, Ian D Davis, et al.Pageof 1